What Is GIP, and Why Does It Matter for Weight Loss Drugs?

Almost everyone who has looked into weight-loss medications has heard of GLP-1. Far fewer have heard of GIP, even though it is the hormone that separates tirzepatide from semaglutide, and even though it was discovered first.

GIP is having a moment. It went from a scientific footnote to the target of several billion-dollar drug programs - and, strangely, two of those programs are pushing in opposite directions. This article explains what GIP actually does, why it was dismissed for decades, and what the research says today.

Nothing here is medical advice. Decisions about medication belong with a healthcare provider.

What does GIP stand for?

Glucose-dependent insulinotropic polypeptide.

It originally stood for something else: gastric inhibitory polypeptide, named for its ability to slow stomach acid secretion. When researchers worked out that its more important job was telling the pancreas to release insulin, they kept the acronym and rewrote the words behind it. The old name still turns up in older papers and in some database entries.

Where does GIP come from?

GIP is made by K-cells lining the duodenum and upper small intestine - the first stretch of gut that food reaches after leaving the stomach. It is released into the blood within minutes of eating.

Its partner hormone, GLP-1, comes from a different cell type (L-cells) further down the digestive tract. Between them they form what physiologists call the incretin system: gut-based hormones that give the pancreas advance notice that fuel is arriving.

GIP responds particularly strongly to fat. Reviews describe it as “secreted most potently in response to high lipid meals,” and note that infusing GIP increases blood flow to fat tissue in lean people and promotes lipid deposition in people with obesity and type 2 diabetes [1].

Like GLP-1, natural GIP lasts only a couple of minutes before an enzyme called DPP-4 destroys it. That is why drugs in this class are engineered to resist that enzyme rather than simply supplying more of the natural hormone.

What does GIP do in the body?

Four main jobs, as the research describes them:

It triggers insulin release when glucose is high. In people without diabetes, GIP accounts for the larger share of the incretin effect - the extra insulin the pancreas produces when glucose arrives through the gut rather than by injection [2].

It manages fat tissue. This is the job GLP-1 cannot do, because fat cells carry GIP receptors and not GLP-1 receptors. GIP helps direct incoming glucose and fat into storage after a meal, which sounds like a bad thing until you consider the alternative - fat circulating in the blood instead.

It acts in the brain. GIP receptors appear in appetite-controlling regions including the area postrema in the brainstem and the hypothalamus [3].

It does not suppress glucagon. This is a clear difference from GLP-1. Some laboratory work even suggests GIP stimulates glucagon release from pancreatic alpha cells [4].

Why was GIP ignored for so long?

Because of one inconvenient fact: GIP’s insulin-releasing power is sharply reduced in people with type 2 diabetes - exactly the group a GIP drug would have been prescribed to.

Reviews put it bluntly: “GIP and GIP receptor agonism had long been viewed as a therapeutic dead end due to the observation that the insulinotropic effect of GIP in most patients with type 2 diabetes is much reduced compared with that observed in healthy individuals” [2].

There was a second strike against it. GIP looked like an obesity-promoting hormone. Post-meal GIP levels are elevated in people with type 2 diabetes and obesity and correlate with waist-to-hip ratio and visceral fat in men. Mice bred without GIP receptors were protected from diet-induced obesity [1].

Put those together and the conclusion looked obvious: GIP makes you fat and does not lower blood sugar in the people who need it. Research money went to GLP-1 instead.

What changed?

Two things.

First, researchers found the GIP resistance was not permanent. Lowering blood glucose - for example with a GLP-1 receptor agonist - partly restores GIP’s insulin-releasing effect [2]. That suggested GIP and GLP-1 might be complementary rather than redundant.

Second, and decisively, Eli Lilly built a molecule to test the idea. Tirzepatide was designed by engineering GLP-1 activity into the human GIP peptide sequence - not the other way around. The stated goal in the 2018 discovery paper was “to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes” [5].

The answer, in mice, was yes: tirzepatide “potently decreased body weight and food intake; these effects were significantly greater than the effects of a GLP-1 receptor agonist” [5]. The clinical program that followed produced the results that made tirzepatide a household name.

What does the GIP arm of tirzepatide actually contribute?

Three areas of evidence, with different levels of certainty.

Fat tissue

Lilly’s own laboratory work, published in Cell Metabolism in 2024, describes GIP receptor activation as a nutrient-partitioning signal. In human fat cells with insulin present, it enhanced insulin signaling, increased glucose uptake and increased conversion of glucose to glycerol. Without insulin, the same signal increased lipolysis - pushing stored fat back out. In obese mice, a long-acting GIP receptor agonist lowered circulating triglycerides during a fat challenge and increased fat uptake into adipose tissue [6].

The authors describe the result as fat tissue doing its buffering job better in both the fed and fasted states.

Insulin sensitivity, independent of weight

Lilly researchers treated obese mice that had been genetically stripped of the GLP-1 receptor, so tirzepatide could only work through GIP. Those mice lost no weight - but their insulin sensitivity improved 1.7-fold, traced to glucose being pulled into white adipose tissue [7].

A 2026 Phase 1b trial in people pushed this further. It gave the selective GIP receptor agonist macupatide alone, dulaglutide alone, or both together to people with type 2 diabetes on metformin. Macupatide alone significantly raised the clamp-measured insulin sensitivity (M value) and, to a smaller degree, insulin secretion rate. The combination beat either alone on every index. The authors concluded that “chronic GIP receptor activation in individuals with T2D leads primarily to increased insulin sensitivity” while GLP-1 activation drives secretion [8].

The brain

Mice engineered without brain GIP receptors are protected from diet-induced obesity, and in those animals a GLP-1/GIP dual agonist loses its advantage over a plain GLP-1 agonist [3]. In 2026, researchers localized the effect: knocking out the GIP receptor specifically in the area postrema abolished the appetite-suppressing effect of an acylated GIP agonist [9].

Importantly, GIP and GLP-1 work through different neurons. GIP receptor agonists need GABAergic neurons; GLP-1 receptor agonists need glutamatergic ones [1]. Two separate levers rather than one lever pressed harder.

The GIP paradox: why are two companies going opposite directions?

Here is the part that confuses even specialists.

Tirzepatide activates the GIP receptor. Amgen’s MariTide blocks it, using an antibody fused to GLP-1 receptor agonist peptides. Both, added to GLP-1 receptor activation, produce more weight loss [2].

That should not be possible if the GIP receptor were a simple on-off switch for body weight. Nature Reviews Endocrinology described the situation in 2026 as a “seeming paradox” [10].

Several explanations are on the table:

Different brain regions. The strongest recent evidence. A 2026 Nature Metabolism study knocked out the GIP receptor separately in the area postrema and in the hypothalamus. Area postrema knockout abolished the appetite effect of GIP agonists but left GIP antagonist synergy intact. Hypothalamic knockout did the reverse - normal response to the agonist, but the antagonist’s added weight loss disappeared [9].

Antagonism disinhibits GLP-1. A 2025 study found the weight and food-intake effects of GIP receptor blockade vanish in mice lacking the GLP-1 receptor, but survive deletion of GIP receptors in GABAergic neurons - the opposite pattern to agonism. Gene-expression profiling showed blockade, not activation, mimics the transcriptional signature of GLP-1 receptor activation in the hindbrain [11].

Chronic activation becomes functional blockade. Some researchers argue that continuously stimulating the GIP receptor desensitizes it so completely that the result resembles blocking it. A 2025 point-counterpoint in Diabetes by Campbell and Drucker called this hypothesis “unifying” but noted “there is currently no evidence to suggest that tirzepatide attenuates activity in GIPR-positive neurons that regulate food intake” [4].

This lane treats the paradox as genuinely unresolved. For a consumer, the practical upshot is that both approaches are in clinical development and neither has been shown to be better than the other.

Does GIP help with nausea?

Possibly, and this is one of the more interesting practical angles.

GIP is anti-emetic in animal models, reducing nausea-related behavior triggered by several different agents [1]. The proposed reason is that GIP-expressing neurons in the brainstem project onto and inhibit the GLP-1 receptor neurons responsible for aversive responses [4].

A small human study tested it. Thirty-two healthy volunteers were put through a deliberately fast liraglutide escalation designed to provoke gut symptoms, once after placebo and once after a single dose of the long-acting selective GIP receptor agonist LY3537021. Total gastrointestinal adverse events fell from 75 to 41 (P = 0.022). Reflux events fell from 14 to 5 (P = 0.005), affecting 13 percent of participants instead of 34 percent [12].

Separately, repeated weekly dosing of that same selective GIP agonist produced weight loss “without gastric emptying delay or nausea and vomiting” [12].

This matters because the reason GLP-1 doses cannot simply be raised indefinitely is nausea and vomiting. If GIP takes some of that edge off, a dual agonist can be pushed to higher total effect. That is the practical argument for what researchers call tirzepatide’s “imbalanced” design - it binds the GIP receptor about as tightly as natural GIP but the GLP-1 receptor roughly five times more weakly than natural GLP-1 [5].

Worth keeping in perspective: tirzepatide’s own label lists nausea, diarrhea, vomiting, constipation and abdominal pain among the reactions reported in at least 5 percent of patients [13]. GIP does not make the drug easy on the stomach; it may just allow more headroom.

Which drugs touch the GIP system?

Drug	What it does to GIP	Status as of September 2026
Tirzepatide (Mounjaro, Zepbound)	Activates GIP receptor and GLP-1 receptor	FDA approved
Retatrutide	Activates GIP, GLP-1 and glucagon receptors	Phase 3; US filing planned early 2027
MariTide (maridebart cafraglutide, Amgen)	Blocks GIP receptor, activates GLP-1 receptor	Investigational
Macupatide (LY3532226, Lilly)	Activates GIP receptor only	Phase 2
Semaglutide (Ozempic, Wegovy, Rybelsus)	No GIP activity at all	FDA approved
Orforglipron (Foundayo, Lilly)	No GIP activity - GLP-1 only, non-peptide	FDA approved April 2026

Sources for approval status: FDA labels and Lilly pipeline disclosures [13][14].

What GIP is not

A few things worth being clear about:

• There is no routine GIP blood test that guides treatment. GIP is measured in research settings, not in clinical practice.
• You cannot meaningfully raise your own GIP through diet in a way that mimics these drugs. Natural GIP is destroyed within minutes; the whole point of the drug engineering is to get around that.
• GIP supplements do not exist as a legitimate category. GIP is a peptide; swallowing one would digest it.
• Having “high GIP” is not a diagnosis. Elevated post-meal GIP is associated with obesity and type 2 diabetes in population studies, but it is not something anyone treats directly.

The bottom line

GIP is the incretin hormone that the field spent decades writing off. It works on fat cells and brain regions that GLP-1 never touches, and its insulin-sensitizing effect appears to run at least partly independent of weight loss.

Tirzepatide is the proof that targeting it can matter clinically. But the biology underneath is still being argued about - most visibly in the fact that blocking the same receptor also produces weight loss. That is the state of the science as of September 2026, and anyone telling you the GIP question is settled is ahead of the evidence.

Sources

1. Douros JD et al. The Premise of the Paradox: Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs - Journal of Clinical Medicine, 2025
2. Rosenkilde MM et al. GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale - Diabetes, 2025
3. The glucose-dependent insulinotropic polypeptide regulates body weight and food intake via CNS-GIPR signaling - Cell Metabolism, 2021
4. Campbell JE, Drucker DJ. Therapeutic Targeting of the GIP Receptor - Revisiting the Controversies - Diabetes, 2025
5. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist - Molecular Metabolism, 2018
6. Regmi A et al. Tirzepatide modulates adipocyte nutrient metabolism through long-acting activation of the GIP receptor - Cell Metabolism, 2024
7. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice - JCI, 2021
8. Heise T et al. Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b Trial - Diabetes, Obesity and Metabolism, 2026
9. Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism - Nature Metabolism, 2026
10. Appetite-suppressing effects of GIPR agonism and antagonism work through different brain regions - Nature Reviews Endocrinology, 2026
11. GIPR agonism and antagonism decrease body weight through different neuronal mechanisms - Nature Metabolism, 2025
12. Knop FK et al. A long-acting GIP receptor agonist improves the gastrointestinal tolerability of GLP-1 receptor agonist therapy - Diabetes, Obesity and Metabolism, 2024
13. Mounjaro (tirzepatide) US Prescribing Information, revised 08/2026 - Eli Lilly
14. Eli Lilly Clinical Development Pipeline, data as of August 5, 2026